CompletedPhase 2NCT01975441
Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa
Studying Filariasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospitals Cleveland Medical Center
- Principal Investigator
- Peter Siba, PhDPapua New Guinea Institution for Medical Research
- Intervention
- Diethylcarbamazine(drug)
- Enrollment
- 182 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2014 – 2018
Study locations (1)
- Papua New Guinean Institute for Medical Research, Maprik, East Sepik Province, Papua New Guinea
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01975441 on ClinicalTrials.govOther trials for Filariasis
Additional recruiting or active studies for the same condition.